Literature DB >> 23912471

Incidence and management of N-acetylcysteine-related anaphylactoid reactions during the management of acute paracetamol overdose.

Takahiro Yamamoto1, Tanya Spencer, Paul I Dargan, David M Wood.   

Abstract

OBJECTIVE: Adverse drug reactions (ADRs) to N-acetylcysteine (NAC) treatment for paracetamol overdose are typically anaphylactoid in origin and occur in 2-48% of treated patients. We explored the incidence and management of NAC ADR in our unit. PATIENTS AND METHODS: Case notes of patients who presented with paracetamol overdose and had ADR to NAC between February 2005 and June 2011 were reviewed. A total of 1648 patients presented with suspected paracetamol overdose and 660 received NAC treatment. Within this group, 82 patients had documented NAC-related ADR.
RESULTS: ADR developed in 12.4% (82/660) of patients receiving intravenous NAC and 59 had full documentation available and were included in this study (34 women, 25 men). ADR occurred in the 15-min (150 mg/kg) bag in 36 cases (61%), 22 in the 4-h (50 mg/kg) bag (37%) and one in the 16-h (100 mg/kg) bag (2%). Symptoms were classified as minimal (n=16, 27%), moderate (n=26, 44%) and severe (n=17, 29%). Asthma and female sex, which are reported risk factors for ADR, did not lead to the development of more severe ADR (P=0.771 and 0.330, respectively). Treatments administered included stopping the NAC infusion (n=32, 54%), administration of antiemetics (n=36, 61%), H1 antihistamines (n=26, 44%), steroids (n=16, 27%), inhaled B2 agonists (n=6, 10%) and adrenaline (n=3, 5%).
CONCLUSION: The incidence of ADR to NAC was comparable with published studies, although there was no association of severity with asthma or female sex. The management of ADRs is variable, with frequent, inappropriate use of steroids. Education about the pathophysiology of these ADRs may improve management.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23912471     DOI: 10.1097/MEJ.0b013e328364eb22

Source DB:  PubMed          Journal:  Eur J Emerg Med        ISSN: 0969-9546            Impact factor:   2.799


  6 in total

1.  Delays during the administration of acetylcysteine for the treatment of paracetamol overdose.

Authors:  George P Bailey; Javad Najafi; Muhammad E M O Elamin; W Stephen Waring; Simon H L Thomas; John R H Archer; David M Wood; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2016-08-10       Impact factor: 4.335

2.  An assessment of the variation in the concentration of acetylcysteine in infusions for the treatment of paracetamol overdose.

Authors:  George P Bailey; David M Wood; John R H Archer; Edmund Rab; Robert J Flanagan; Paul I Dargan
Journal:  Br J Clin Pharmacol       Date:  2016-09-29       Impact factor: 4.335

3.  Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase.

Authors:  Jephte Y Akakpo; Anup Ramachandran; Luqi Duan; Matthew A Schaich; Matthew W Jaeschke; Bret D Freudenthal; Wen-Xing Ding; Barry H Rumack; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

Review 4.  Evidence for the changing regimens of acetylcysteine.

Authors:  Angela L Chiew; Geoffrey K Isbister; Stephen B Duffull; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-11-23       Impact factor: 4.335

5.  Post-treatment with glycyrrhizin can attenuate hepatic mitochondrial damage induced by acetaminophen in mice.

Authors:  Xue-Liang Dang; Long-Fei Yang; Lei Shi; Long-Fei Li; Ping He; Jie Chen; Bei-Jie Zheng; Peng Yang; Ai-Dong Wen
Journal:  Exp Biol Med (Maywood)       Date:  2020-12-20

6.  The Potential Protective Effect of Curcumin and α-Lipoic Acid on N-(4-Hydroxyphenyl) Acetamide-induced Hepatotoxicity Through Downregulation of α-SMA and Collagen III Expression.

Authors:  Ahlam Alhusain; Laila Fadda; Wedad Sarawi; Hatun Alomar; Hanaa Ali; Raeesa Mahamad; Iman Hasan; Amira Badr
Journal:  Dose Response       Date:  2022-02-24       Impact factor: 2.658

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.